Abstract: The present invention relates to polynucleotides encoding immunogenic HIV type C polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of HIV Type C proteins are also described.
Type:
Grant
Filed:
July 5, 2001
Date of Patent:
November 17, 2009
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Jan zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse van Rensburg
Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.
Type:
Grant
Filed:
November 22, 2006
Date of Patent:
May 5, 2009
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
Abstract: N-[1-oxo-2-alkyl-3-(N-hydroxyformamido)-propyl]-(carbonylamino-aryl or -heteroaryl)-azacyclo4-7alkanes or thiazacyclo4-7alkanes or imidazacyclo4-7alkanes have interesting properties, e.g., in the treatment or prevention of disorders amenable to treatment by peptidyl deformylase inhibitors such as treatment of bacterial infections.
Type:
Grant
Filed:
June 14, 2002
Date of Patent:
December 12, 2006
Assignee:
Novartis AG
Inventors:
Jeffrey Jacobs, Rakesh K. Jain, Dinesh V. Patel, Zhengyu Yuan
Abstract: A method of treatment of: i) HIV-1 infections in mammals, including humans; or ii) HBV infections in mammals, including humans; which method comprises the administration to the human in need of such treatment, an effective amount of the (R)-enantiomer of the triphosphate of a compound of formula (A) or a pharmaceutically acceptable salt thereof; and compounds for use in the method.
Type:
Grant
Filed:
April 23, 1996
Date of Patent:
May 16, 2006
Assignee:
Novartis AG
Inventors:
Richard Anthony Vere Hodge, Raymond F Schinazi
Abstract: Transgenic flies displaying altered phenotypes due to expression of the Abeta and C99 portions of the human APP gene are disclosed. Use of these flies in a method to identify Drosophila genes and the human homologs of these Drosophila genes, that are potentially involved in Alzheimer's Disease, is also disclosed. The use of said human homologs as drug targets for the development of therapeutics to treat Alzheimer's Disease and other conditions associated with defects in the APP pathway, as well as pharmaceutical compositions comprising substances directed to these genes, are also disclosed.
Type:
Grant
Filed:
September 27, 2001
Date of Patent:
May 31, 2005
Assignee:
Novartis
Inventors:
Dalia Cohen, Uwe Jochen Dengler, Alyce Lynn Finelli, Felix Freuler, Mary Konsolaki, Mischa Werner Henri Marie Reinhardt, Susan Zusman
Abstract: The present invention provides various methods for utilizing a polypeptide encoding a chemokine (MEC) and a polypeptide translated therefrom. The MEC chemokine is underexpressed in tumors, making the chemokine a useful marker for diagnosis and prognosis of adverse bodily reactions.
Type:
Grant
Filed:
March 21, 2001
Date of Patent:
December 21, 2004
Assignee:
Novartis
Inventors:
Mark A. Labow, Craig Stephen Mickanin, Umesh Bhatia